Crearene and Alzchem Group: Study on creatine supplementation during hemodialysis now successfully completed
Alzchem Group AG and Crearene AG announced in October 2023 that they have jointly initiated a clinical study to investigate the use of creatine in dialysis treatments. The feasibility, safety and dose-finding study has now been fully completed. The team from the University Medical Center Groningen, led by Prof. Dr. Stephan J.L. Bakker, used specially purified creatine from the Alzchem Group.
All three study objectives were achieved. The study confirmed the technical feasibility of simultaneous creatine administration during hemodialysis treatment and that creatine administration via the dialysis solution is well tolerated by patients with end-stage chronic kidney disease. It also provided clear results on the effective dosage of creatine solution during the dialysis process to replenish missing creatine in the body.
Positive absorption gradients of creatine in the human body were confirmed by three independent methods.
In addition to the primary research objectives, initial observations were made on clinically relevant efficacy parameters. Based on these observations, hand grip strength (HGS) as a typical test of patients' physical condition can be selected as an endpoint for further evaluation. HGS has been shown to be a relevant indicator of patients’ health status in other studies.
Alzchem Group AG and Crearene AG as development partners are pleased with the results, which provide a solid basis for product formulation and a rapid market launch.
Web links: https://crearene.com/ and https://www.alzchem.com/
Contact
Sabine Sieber
Head of Corporate Communications & Investor Relations
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
About Alzchem
Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem offers answers to various global developments such as climate change, population growth and increasing life expectancy. We deliver solutions through brands and products of the highest quality and through a sustainable vision to help shape global developments.
The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.
Alzchem Group AG’s broad product range includes dietary supplements, precursors for PCR tests and pharmaceutical raw materials. These offerings are the company’s response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.
The company employs around 1,690 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and England. Alzchem generated Group sales of EUR 540.6 million and EBITDA of EUR 81.4 million in 2023.